{"id":629625,"date":"2024-09-03T16:26:51","date_gmt":"2024-09-03T20:26:51","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=629625"},"modified":"2025-10-23T18:29:24","modified_gmt":"2025-10-23T22:29:24","slug":"rybelsus-vs-wegovy","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/rybelsus-vs-wegovy\/","title":{"rendered":"Rybelsus vs. Wegovy: Differences, similarities & side effects"},"content":{"rendered":"

Rybelsus<\/span><\/a> and <\/span>Wegovy<\/span><\/a> are two brand-name medications that both contain the active ingredient semaglutide. While Rybelsus is used to manage <\/span>blood sugar levels<\/span><\/a> in people with <\/span>Type 2 diabetes<\/span><\/a>, Wegovy is prescribed for weight management and reducing cardiovascular risk. Rybelsus is taken by mouth once a day, whereas Wegovy is injected under the skin once a week. Despite containing the same active ingredient, these medications differ in other areas, such as their administration methods, dosing schedules, and approved Food and Drug Administration (FDA) indications. Continue reading to learn more about Rybelsus and Wegovy.<\/span><\/p>\n

Rybelsus vs. Wegovy: Key differences<\/span><\/h2>\n

Rybelsus and Wegovy are both medications containing semaglutide, a <\/span>glucagon-like peptide-1 (GLP-1) receptor agonist<\/span><\/a>. Rybelsus is approved by the FDA\u00a0 to manage blood sugar (blood glucose) levels in people with Type 2 diabetes. Wegovy is FDA approved for weight management and to reduce cardiovascular risk. Rybelsus is taken orally once daily, and Wegovy is a weekly injection. Both medications are available only as brand-name drugs, with no generics currently available.<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Compare Rybelsus vs. Wegovy key differences<\/span><\/h3>\n<\/th>\n<\/tr>\n<\/thead>\n

<\/td>\nRybelsus<\/b><\/td>\nWegovy<\/b><\/td>\n<\/tr>\n
Drug class<\/b><\/td>\nGLP-1 receptor agonist<\/span><\/td>\nGLP-1 receptor agonist<\/span><\/td>\n<\/tr>\n
Brand\/generic status<\/b><\/td>\nBrand<\/span><\/td>\nBrand<\/span><\/td>\n<\/tr>\n
What is the generic name?<\/b><\/td>\nThe active ingredient is semaglutide, but there is not a generic available<\/span><\/td>\nThe active ingredient is semaglutide, but there is not a generic available<\/span><\/td>\n<\/tr>\n
What form(s) does the drug come in?<\/b><\/td>\nOral tablet: 3 mg, 7 mg, and 14 mg<\/span><\/td>\nInjection: <\/span>0.25 mg per injection, 0.5 mg per injection, 1 mg per injection, 1.7 mg per injection, and 2.4 mg per injection<\/span>\u00a0<\/span><\/td>\n<\/tr>\n
What is the standard dosage?<\/b><\/td>\nThe starting dose is 3 mg by mouth once a day for 30 days. After that, the dose may be increased to a higher dose of 7 mg by mouth once a day. After at least 30 days, the dose may stay the same or be increased to 14 mg daily if needed to control blood sugar.\u00a0<\/span><\/td>\nThe <\/span>starting dose<\/span><\/a> is 0.25 mg, injected once a week for 4 weeks under the skin of the upper arm, stomach, or thigh. The dose will be gradually increased to 1.7 mg or 2.4 mg injected weekly.\u00a0<\/span><\/td>\n<\/tr>\n
How long is the typical treatment?<\/b><\/td>\nLong-term<\/span><\/td>\nLong-term<\/span><\/td>\n<\/tr>\n
Who typically uses the medication?<\/b><\/td>\nAdults\u00a0<\/span><\/td>\nWeight management: Adults and pediatric patients 12 years and older<\/span><\/p>\n

Cardiovascular risk reduction: Adults\u00a0<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Rybelsus vs. Wegovy: Conditions treated<\/span><\/h2>\n

Rybelsus<\/span><\/a> is FDA approved to improve blood sugar control in adults with Type 2 diabetes mellitus. It is often recommended along with lifestyle changes such as a reduced-calorie diet and exercise. Some healthcare providers may prescribe Rybelsus off-label for weight loss, although it is not specifically FDA approved for this use.\u00a0<\/span><\/p>\n

Wegovy has two FDA-approved uses and is also generally recommended along with diet and exercise:\u00a0<\/span><\/p>\n